NIH head: Coronavirus 'good candidate' for vaccine
Friday, 29 May 2020 Dr. Francis Collins, the director of the National Institutes of Health (NIH) in Bethesda, Maryland, says that the coronavirus is a "good candidate" for medical researchers to accomplish finding a vaccine. (May 29)
When will the coronavirus vaccine be ready? Epidemiologist Seth Berkley (head of Gavi, the Vaccine Alliance) takes us inside the effort to create a vaccine for COVID-19. With clarity and urgency, he explains what makes it so challenging to develop, when we can expect it to be rolled out at scale and...
The nation's top infectious disease expert says the status of the coronavirus pandemic in the US is 'really not good.' Dr. Anthony Fauci made the remark Monday in a Facebook Live interview with National Institutes of Health Director Dr. Francis Collins. He expressed dismay over people congregating in crowds, not wearing masks, and inadequate attention being paid to guidelines on reopening. According to CNN, nearly 3 million Americans have been infected with the virus. More than 129,000 have died. We're going to continue to be in a lot of trouble," he said. "And there's going to be a lot of hurt if that does not stop. Dr. Anthony Fauci Director, National Institute of Allergies and Infectious Diseases.
A team of chemists from HSE University and the Zelinsky Institute of Organic Chemistry used molecular modelling to find out that two medications that have been known for a long time can be used to fight SARS-CoV-2. These are disulfiram, which is used to treat alcoholism, and neratinib, an experimental drug being used to treat breast cancer. The paper about the discovery has been published online in the 4th issue of Mendeleev Communications journal.The structural elements of the virus that are less subject to mutation during its evolution should be chosen as a target for the potential treatment. Otherwise, a medication effective against one strain would no longer be effective against another. The best candidates for this are conservative proteins, such as the SARS-CoV-2 virus main protease M pro. In addition to being resistant to mutations, M pro plays a major role in coronavirusreplication, which means that its inhibition (blocking its function) is able to slow down or even completely stop its reproduction inside the body.Usually, the process of docking, as with a port dock and a ship entering it, is used for molecular modelling in simple cases. Two molecules participate in docking. One is called a 'ligand' (here, it is a medicine), and the other one is 'receptor' (or active site) of the target protein, such as Mpro, which can be used to 'dock'. An effective drug docks with the active site, by covalent links, which makes the enzyme dysfunctional or destroys it. But classical docking does not work in SARS-CoV-2.To overcome this problem, chemists from HSE University and the Zelinsky Institute decided to use 'on-top docking', which they came up with shortly before the pandemic. 'We decided not to focus on the previously described active site, but to investigate the whole surface of M pro protein with many medications, hoping that the big calculation powers would return useful "dockings",' - said Igor Svitanko, the author of the article,Professor at the HSE Joint Department of Organic Chemistry with the RAS Zelinsky Institute of Organic Chemistry.
[NFA] Tropical Storm Isaias raced up the U.S. East Coast on Tuesday, generating tornadoes and knocking out power, and a twister in North Carolina killed at least one person when it obliterated a mobile home park. This report produced by Yahaira Jacquez.
Maryland-based biotechnology company, Novavax, said on Tuesday its experimental COVID-19 vaccine produced antibodies against the novel coronavirus and appears to be safe, according to an early-stage study. President of Research and Development, Dr. Gregory Glenn told Reuters the experimental vaccine “looked good in animals. Now it looks really good in people."